Opinion

Video

Key Findings from the NADINA Trial at ASCO 2024

Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.

Video content above is prompted by the following:

  • Discuss the data presented at the 2024 ASCO Annual Meeting on the phase 3 NADINA trial (NCT04949113) of neoadjuvant nivolumab plus ipilimumab vs adjuvant nivolumab in patients with macroscopic, resectable stage III melanoma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study. How might these findings impact the treatment of patients with melanoma?
  • What are the key considerations when deciding between neoadjuvant and adjuvant therapy for patients with resectable melanoma?
Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
This series features 1 KOL.
1 KOL is featured in this series.
This series features 1 kol.
This series features 1 KOL.
This series features 1 KOL.
This series features 1 kol.
Related Content

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo